



Post Authorisation Assessments

Strantel Plus XL Tablets for Dogs

| | | |
|---|------------------|---|
| • | 20 April 2022 | Update to ASMF. |
| • | 20 January 2022 | Deletion of manufacturing site for an active substance. |
| • | 22 April 2021 | Deletion of manufacturing site for an active substance. Submission of an updated Ph. Eur. certificate of suitability for an active substance from an already approved manufacturer. Submission of an updated Ph. Eur. certificate of suitability for an active substance from an already approved manufacturer. Submission of a new Ph. Eur. certificate of suitability for an active substance from a new manufacturer. |
| • | 12 November 2019 | Increase in the shelf-life of the finished product as packaged for sale, from 3 years to 5 years. |
| • | 15 July 2019 | Submission of an updated Ph. Eur. certificate of suitability for an active substance from an already approved manufacturer |
| • | 13 June 2019 | Change in the invented name of the Italian veterinary medicinal product from Exitel Plus XL tablets for dogs to Panadron Plus XL compresse per cani |
| • | 10 January 2019 | Submission of a new Ph. Eur. certificate of suitability for an active substance from a new manufacturer. |
| • | 02 July 2018 | ASMF updated. |
| • | 22 December 2017 | Addition of a new Ph. Eur. certificate of suitability for an active substance from a new manufacturer. |
| • | 12 April 2017 | Renewal – UK as CMS |
| • | 15 May 2015 | Submission of a new certificate of suitability. |
| • | 06 November 2011 | Change to the invented name of the veterinary medicinal product in the UK from Exitel Plus XL Tablets for Dogs to Strantel Plus XL Tablets for Dogs. Submission of two updated Certificates of suitability. |
| • | 10 October 2013 | Change in test procedure for the finished product. |